Clinical Trials
16 trialsNCT07467629 2026-05-19
QLS5212 for Participants With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT07584954 2026-05-13
Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors
ImmunoUrchin
Phase 1 Recruiting
NCT07492173 2026-03-25
Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans
Shandong New Time Pharmaceutical Co., LTD
Phase NA Completed
NCT07441174 2026-02-27
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT07257497 2025-12-02
Safety and Efficacy of Combining a Vitamin B6-Limited Diet With Immunotherapy in Solid Tumor Patients: A Clinical Study Protocol
West China Hospital
Phase 1 Not yet recruiting
NCT07117461 2025-10-16
A Study of a Distress Screening and Referral Program in People With Recently Diagnosed Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT07146672 2025-08-28
Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors
Shanghai Cell Therapy Group Co.,Ltd
Phase 1/2 Recruiting
NCT07038044 2025-06-26
Safety and Efficacy of an Arginine-Restricted Diet in Patients With Solid Tumors
West China Hospital
Phase 1 Not yet recruiting
NCT06962254 2025-05-08
Imatinib and Trametinib for KRAS-mutated Solid Tumor
China Medical University Hospital
Phase 1 Recruiting
NCT06597786 2025-03-17
A Study of Exercise Therapy in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT06710821 2024-11-29
Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors
Sun Yat-sen University
Phase 1 Not yet recruiting
NCT06649448 2024-10-18
EF-001
Shandong Cancer Hospital and Institute
Phase NA Not yet recruiting
NCT00085878 2008-10-16
Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00119171 2008-10-16
Ispinesib In Combination With Capecitabine In Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00136513 2008-10-16
SB-743921 In Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00169520 2008-10-16
SB-715992 In Combination With Docetaxel In Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed